Evidence map›Paper›PMID 28587082›Full record

ReviewMolecules (Basel, Switzerland)2017

Natural Products as Alternative Choices for P-Glycoprotein (P-gp) Inhibition.

Saikat Dewanjee, Tarun K Dua, Niloy Bhattacharjee, Anup Das, Moumita Gangopadhyay, Ritu Khanra, Swarnalata Joardar, Muhammad Riaz, Vincenzo De Feo, Muhammad Zia-Ul-Haq

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 200 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Extracts fromFrontiers in pharmacology · 2026
    Article
  6. SoloxoloneInternational journal of molecular sciences · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Journal of traditional and complementary medicine · 2025
    Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Saikat DewanjeeAdvanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India. s.dewanjee@yahoo.com.
Tarun K DuaAdvanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India. tarunkduaju@gmail.com.
Niloy BhattacharjeeAdvanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India. bniloy5@gmail.com.
Anup DasDepartment of Pharmaceutical Technology, ADAMAS University, Barasat, Kolkata 700126, India. anup.das82@gmail.com.
Moumita GangopadhyayDepartment of Bioechnology, ADAMAS University, Barasat, Kolkata 700126, India. gangopadhyaymoumita75@gmail.com.
Ritu KhanraAdvanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India. ritukhanra@yahoo.co.in.
Swarnalata JoardarAdvanced Pharmacognosy Research Laboratory, Department of Pharmaceutical Technology, Jadavpur University, Raja S C Mullick Road, Kolkata 700032, India. swarnalatajoardar@yahoo.in.
Muhammad RiazDepartment of Pharmacy, Shaheed Benazir Bhutto University, Sheringal 18050, Pakistan. pharmariaz@gmail.com.
Vincenzo De FeoDepartment of Pharmacy, Salerno University, Fisciano 84084, Salerno, Italy. defeo@unisa.it.
Muhammad Zia-Ul-HaqEnvironment Science Department, Lahore College for Women University, Jail Road, Lahore 54600, Pakistan. ahirzia@gmail.com.
Jadavpur University · INAdamas University · INLahore College for Women University · PKShaheed Benazir Bhutto University · PKUniversity of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is regarded as one of the bottlenecks of successful clinical treatment for numerous chemotherapeutic agents. Multiple key regulators are alleged to be responsible for MDR and making the treatment regimens ineffective. In this review, we discuss MDR in relation to P-glycoprotein (P-gp) and its down-regulation by natural bioactive molecules. P-gp, a unique ATP-dependent membrane transport protein, is one of those key regulators which are present in the lining of the colon, endothelial cells of the blood brain barrier (BBB), bile duct, adrenal gland, kidney tubules, small intestine, pancreatic ducts and in many other tissues like heart, lungs, spleen, skeletal muscles, etc. Due to its diverse tissue distribution, P-gp is a novel protective barrier to stop the intake of xenobiotics into the human body. Over-expression of P-gp leads to decreased intracellular accretion of many chemotherapeutic agents thus assisting in the development of MDR. Eventually, the effectiveness of these drugs is decreased. P-gp inhibitors act by altering intracellular ATP levels which are the source of energy and/or by affecting membrane contours to increase permeability. However, the use of synthetic inhibitors is known to cause serious toxicities. For this reason, the search for more potent and less toxic P-gp inhibitors of natural origin is underway. The present review aims to recapitulate the research findings on bioactive constituents of natural origin with P-gp inhibition characteristics. Natural bioactive constituents with P-gp modulating effects offer great potential for semi-synthetic modification to produce new scaffolds which could serve as valuable investigative tools to recognize the function of complex ABC transporters apart from evading the systemic toxicities shown by synthetic counterparts. Despite the many published scientific findings encompassing P-gp inhibitors, however, this article stand alones because it provides a vivid picture to the readers pertaining to Pgp inhibitors obtained from natural sources coupled with their mode of action and structures. It provides first-hand information to the scientists working in the field of drug discovery to further synthesise and discover new P-gp inhibitors with less toxicity and more efficacies.

Indexed as

AnimalsAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBiological ProductsDrug DiscoveryDrug Resistance, MultipleDrug Resistance, NeoplasmGene ExpressionHumansModels, BiologicalModels, MolecularMolecular StructureProtein BindingProtein TransportStructure-Activity RelationshipAntineoplastic AgentsATP Binding Cassette Transporter, Subfamily BBiological ProductsABC transporterschemotherapymulti drug resistance (MDR)P-glycoprotein (P-gp)P-gp inhibitorsxenobiotics

Identifiers

PMID28587082
PMCPMC6152721
OpenAlexW2618656701

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.